HomeCompareALBO vs GBDC

ALBO vs GBDC: Dividend Comparison 2026

ALBO yields 4.53% · GBDC yields 11.85%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GBDC wins by $20.75M in total portfolio value
10 years
ALBO
ALBO
● Live price
4.53%
Share price
$44.15
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26.9K
Annual income
$605.56
Full ALBO calculator →
GBDC
GBDC
● Live price
11.85%
Share price
$12.66
Annual div
$1.50
5Y div CAGR
51.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.78M
Annual income
$16,389,263.41
Full GBDC calculator →

Portfolio growth — ALBO vs GBDC

📍 GBDC pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodALBOGBDC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ALBO + GBDC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ALBO pays
GBDC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ALBO
Annual income on $10K today (after 15% tax)
$385.05/yr
After 10yr DRIP, annual income (after tax)
$514.73/yr
GBDC
Annual income on $10K today (after 15% tax)
$1,007.11/yr
After 10yr DRIP, annual income (after tax)
$13,930,873.90/yr
At 15% tax rate, GBDC beats the other by $13,930,359.17/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ALBO + GBDC for your $10,000?

ALBO: 50%GBDC: 50%
100% GBDC50/50100% ALBO
Portfolio after 10yr
$10.40M
Annual income
$8,194,934.48/yr
Blended yield
78.79%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ALBO right now

ALBO
Analyst Ratings
7
Buy
5
Hold
Consensus: Buy
Price Target
$44.00
-0.3% upside vs current
Range: $42.00 — $48.00
Altman Z
0.5
Piotroski
4/9
GBDC
Analyst Ratings
6
Buy
5
Hold
Consensus: Buy
Price Target
$14.00
+10.6% upside vs current
Range: $13.00 — $15.00
Altman Z
0.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ALBO buys
0
GBDC buys
0
No recent congressional trades found for ALBO or GBDC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricALBOGBDC
Forward yield4.53%11.85%
Annual dividend / share$2.00$1.50
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%51.1%
Portfolio after 10y$26.9K$20.78M
Annual income after 10y$605.56$16,389,263.41
Total dividends collected$5.3K$20.36M
Payment frequencyquarterlyquarterly
SectorStockBDC
Analyst consensusBuyBuy
Analyst price target$44.00$14.00

Year-by-year: ALBO vs GBDC ($10,000, DRIP)

YearALBO PortfolioALBO Income/yrGBDC PortfolioGBDC Income/yrGap
1← crossover$11,153$453.00$12,490$1,790.28$1.3KGBDC
2$12,406$472.18$16,522$3,157.73$4.1KGBDC
3$13,765$490.86$23,578$5,898.68$9.8KGBDC
4$15,238$509.01$37,115$11,886.75$21.9KGBDC
5$16,831$526.60$66,136$26,423.57$49.3KGBDC
6$18,553$543.61$137,257$66,491.44$118.7KGBDC
7$20,411$560.02$341,734$194,868.54$321.3KGBDC
8$22,416$575.82$1,050,788$685,133.02$1.03MGBDC
9$24,576$591.00$4,099,314$2,974,971.01$4.07MGBDC
10$26,902$605.56$20,775,530$16,389,263.41$20.75MGBDC

ALBO vs GBDC: Complete Analysis 2026

ALBOStock

Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as well as in Phase III clinical trial for treating biliary atresia, alagille syndrome, and rare and life-threatening disorder to children; and Elobixibat for the treatment of chronic constipation and other functional diseases. It also engages in the developing of A3907, which is in Phase I clinical trial for the treatment of adult liver diseases; and A2342, a preclinical candidate to treat adult viral and liver diseases. The company has a license agreement with EA Pharma Co., Ltd. for the development and commercialization of elobixibat. Albireo Pharma, Inc. is headquartered in Boston, Massachusetts.

Full ALBO Calculator →

GBDCBDC

Golub Capital BDC, Inc. (GBDC) is a business development company and operates as an externally managed closed-end non-diversified management investment company. It invests in debt and minority equity investments in middle-market companies that are, in most cases, sponsored by private equity investors. It typically invests in diversified consumer services, automobiles, healthcare technology, insurance, health care equipment and supplies, hotels, restaurants and leisure, healthcare providers and services, IT services and specialty retails. It seeks to invest in the United States. It primarily invests in first lien traditional senior debt, first lien one stop, junior debt and equity, senior secured, one stop, unitranche, second lien, subordinated and mezzanine loans of middle-market companies, and warrants.

Full GBDC Calculator →
📬

Get this ALBO vs GBDC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ALBO vs SCHDALBO vs JEPIALBO vs OALBO vs KOALBO vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.